Abstract Library

#4666 Merkel cell neuroendocrine carcinoma of the skin: High response rates to short course palliative radiotherapy – Typical clinical scenarios

Introduction: Merkel cell carcinomas (MCC) are a rare, aggressive skin neuroendocrine carcinomas, with peak incidence in the elderly. MCC often presents as a firm, red/purple painless nodule with a short history of increasing size. Surgery is considered the 1st line treatment but elderly patients, in particular, have comorbidities which may preclude radical surgery requiring reconstruction. In advanced MCC, immunotherapy (IO) is 1st line systemic treatment. Chemotherapy is used 2nd line or if contraindications for IO but can be challenging in an elderly population. There may be an emerging role for PRRT due to the presence of somatostatin receptors on MCC. Radiotherapy (RT) can be used for non-surgical candidates, or those with unresectable or metastatic disease. Adjuvant post-operative irradiation (PORT) may provide additional benefit in risk reduction and improves local control.

Conference:

Presenting Author:

Authors: Saunders E, Sizer B, Collins J, Skelly R, Srinivasan G,

Keywords: Merkel cell, skin, radiotherapy,

#4223 US real-world study of the burden of medication in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Patients with NETs experience a range of comorbidities, and often present with carcinoid syndrome (CS).

Conference:

Presenting Author:

Authors: Chan J, Houchard A, Pommie C, Ribeiro-Oliveira Jr A, Starr J,

Keywords: gastroenteropancreatic, neuroendocrine tumor, concomitant medication, burden,

#4190 Burden of medication in patients with lung neuroendocrine tumors (NETs) in a US real-world setting

Introduction: Real-world evidence on patients with lung NETs, specifically on comorbidities and the prevalence of carcinoid syndrome (CS), is lacking.

Conference:

Presenting Author:

Authors: Starr J, Houchard A, Pommie C, Ribeiro-Oliveira Jr A, Chan J,

Keywords: lung, neuroendocrine tumor, concomitant medication, costs,

#4156 Status of the ongoing SORENTO clinical trial: Assessing efficacy and safety of high-exposure octreotide subcutaneous depot in patients with GEP-NET

Introduction: Somatostatin receptor ligands (SRLs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET). Retrospective data suggest higher-dose SRLs may benefit patients with GEP-NET.

Conference:

Presenting Author: Singh S

Authors: Singh S, Capdevila J, Ang Chan J, de Herder W, Grozinsky-Glasberg S,

Keywords: CAM2029, GEP-NET, high plasma exposure, octreotide, randomised active-controlled, somatostatin receptor ligands, SORENTO,

#3620 Real-world SEER-Medicare data analysis of the evolution of tumor characteristics, first-line therapies and overall survival (OS) in patients with neuroendocrine tumors (NETs)

Introduction: Recent data on NET therapy utilization and impact in real-world practice are scarce.

Conference:

Presenting Author:

Authors: Schneider M, Sinha A, Dasari A, Chan J, Stoffels A,

Keywords: neuroendocrine tumor, NET characteristics, first-line therapy, treatment evolution, treatment patterns, overall survival,